Russian vaccine against COVID-19 sparks interest abroad

Sputnik V, the Russian coronavirus vaccine, will undergo laboratory tests in Serbia, Remedium reports. 20 doses of the vaccine will be delivered to the country by the end of this week. Serbian officials said they are ready to explore the possibility of joint production of the vaccine.

Meanwhile, it became known earlier that the EpiVacCorona vaccine, created by the Vector Center, will be tested on adolescents 14-17 years old in December. On the group "over 60" tests are already underway. New research should be conducted in six stages with decreasing age.

Rinat Maksyutov, general director of the center, commented: “The first clinical trial of a vaccine is carried out on children aged 14 to 17 years. If it is successful, they pass to the next age - with a decrease. six months.

We are ready to launch clinical studies on adolescents between the ages of 14 and 17 in December this year when we make such a decision because this category of the population is susceptible to coronavirus. "